Form 8-K Karyopharm Therapeutics For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Karyopharm Therapeutics (KPTI) Initiates Selinexor Phase 2 in SIRRT Patients
November 10, 2014 7:22 AM ESTKaryopharm Therapeutics (Nasdaq: KPTI) announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients with Richter's transformation (SIRRT) that is relapsed after or refractory to chemotherapy. This multi-center study of Selinexor, one of the company's novel, oral Selective Inhibitor of Nuclear Export / SINE compounds, will enroll approximately 50 patients in approximately 35 sites worldwide.
This single arm, open-label, Phase 2 study will... More
Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 9c
November 10, 2014 7:21 AM ESTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52).
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
... More